Evaluation of the Hemodynamic Significance of Myocardial Bridge by Coronary Blood Fractional Flow Reserve

NCT04958395 | Completed

• 1 other identifier: 2014188
• Study Type: observational
• Target: 20
• Locations: 0 countries
• Sites: N/A

Brief Summary

This study clarified the influence of myocardial bridge on coronary hemodynamics by clarifying FFR and d-FFR to guide clinical intervention and treatment.

Conditions

Myocardial Bridge

Outcome Measures

Primary Outcomes (1)

• Morphological index of myocardial bridge

  The minimum lumen diameter of the target vessel

  All indicators were completed within 1 week of coronary angiography.

Secondary Outcomes (1)

• Exercise electrocardiogram

  72 hours after coronary angiography

Study Arms (1)

Myocardial bridge

Measure FFR and d-FFR

Diagnostic Test: FFR and d-FFR

Interventions

FFR and d-FFR DIAGNOSTIC_TEST

Measure FFR and d-FFR

Myocardial bridge

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

The investigators enrolled patients with LAD simple myocardial bridge after other interventional treatments for vascular lesions or FFR testing to exclude functionally significant lesions.

You may qualify if:

• Patients with chest pain aged ≥18 years old, regardless of gender;
• Coronary angiography shows a solitary myocardial bridge with systolic diameter stenosis ≥30% in LAD;
• Have the ability to complete an ECG exercise test;
• Sign informed consent and are willing to participate in the intended study.

You may not qualify if:

• Patients with acute coronary syndrome;
• Coronary angiography shows that the diameter of atherosclerosis in the non-myocardial bridge area of LAD is ≥30%;
• RCA or LCX has severe fixed stenosis, diameter stenosis ≥70% or FFR\<0.75, and no interventional therapy is accepted;
• Hypertrophic obstructive cardiomyopathy or more than moderate heart valve disease;
• Atrial fibrillation or severe slow or rapid arrhythmia;
• Heart failure with NYHA ≥ Grade III;
• Uncontrolled hypertension or systolic blood pressure \<100mmHg;
• Asthma or severe chronic obstructive pulmonary disease;
• Severe liver and kidney dysfunction;
• Allergic to contrast agents.

Sponsors & Collaborators

• Peking University Third Hospital: lead

MeSH Terms

Conditions

Myocardial Bridging

Condition Hierarchy (Ancestors)

Coronary Vessel Anomalies; Heart Defects, Congenital; Cardiovascular Abnormalities; Cardiovascular Diseases; Heart Diseases; Congenital Abnormalities; Congenital, Hereditary, and Neonatal Diseases and Abnormalities

Study Officials

• Liyun He

  Peking University Third Hospital

  STUDY DIRECTOR

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 27, 2021
• First Posted: July 12, 2021
• Study Start: November 1, 2014
• Primary Completion: October 31, 2015
• Study Completion: October 31, 2015
• Last Updated: July 12, 2021

Record last verified: 2014-11

Data Sharing

• IPD Sharing: Will not share